|drug3862||TAK-671 Placebo Wiki||1.00|
There is one clinical trial.
The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.
Description: Combined of need for ICU or mortalityMeasure: Need for ICU or mortality Time: 30 days
Description: Evaluate correlation between hs-TnT and covid-19 severityMeasure: High sensitivity troponin levels and covid-19 severity Time: 30 days
Description: Evaluate correlation of ACE-2 activity and disease severityMeasure: ACE-2 activity and disease severity Time: 30 days
Description: Evaluate correlation of ACE-2 activity and Renin-angiotensin system inhibitorsMeasure: ACE-2 activity with different Renin-angiotensin system inhibitors Time: 30 days
Description: Evaluate blood pressure control and acute renal failure in each arm (safety)Measure: Blood control and acute renal failure Time: 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports